Your browser doesn't support javascript.
loading
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.
Stratigos, Alexander J; Garbe, Claus; Dessinioti, Clio; Lebbe, Celeste; van Akkooi, Alexander; Bataille, Veronique; Bastholt, Lars; Dreno, Brigitte; Dummer, Reinhard; Fargnoli, Maria Concetta; Forsea, Ana Maria; Harwood, Catherine A; Hauschild, Axel; Hoeller, Christoph; Kandolf-Sekulovic, Lidija; Kaufmann, Roland; Kelleners-Smeets, Nicole Wj; Lallas, Aimilios; Leiter, Ulrike; Malvehy, Josep; Del Marmol, Veronique; Moreno-Ramirez, David; Pellacani, Giovanni; Peris, Ketty; Saiag, Philippe; Tagliaferri, Luca; Trakatelli, Myrto; Ioannides, Dimitrios; Vieira, Ricardo; Zalaudek, Iris; Arenberger, Petr; Eggermont, Alexander M M; Röcken, Martin; Grob, Jean-Jacques; Lorigan, Paul.
Affiliation
  • Stratigos AJ; First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece. Electronic address: alstrat2@gmail.com.
  • Garbe C; Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.
  • Dessinioti C; First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece.
  • Lebbe C; Université Paris Cite, Dermato-Oncology AP-HP Hôpital Saint Louis, Cancer Institute APHP. Nord-Université Paris Cite, INSERM U976, Paris, France.
  • van Akkooi A; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia.
  • Bataille V; Mount Vernon Cancer Centre, East and North NHS Trust, Northwood, UK.
  • Bastholt L; Department of Oncology, Odense University Hospital, Odense, Denmark.
  • Dreno B; Nantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France.
  • Dummer R; Skin Cancer Centre at University Hospital Zurich, Zurich, Switzerland.
  • Fargnoli MC; Dermatology Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Forsea AM; Carol Davila University of Medicine and Pharmacy Bucharest, Department of Oncologic Dermatology, Elias University Hospital Bucharest, Bucharest, Romania.
  • Harwood CA; Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Hauschild A; Department of Dermatology, University Hospital (UKSH), Kiel, Germany.
  • Hoeller C; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Kandolf-Sekulovic L; Department of Dermatology, Medical Faculty, Military Medical Academy, Belgrade, Serbia.
  • Kaufmann R; Department of Dermatology, Venereology and Allergology, Frankfurt University Hospital, Frankfurt, Germany.
  • Kelleners-Smeets NW; GROW-School for Oncology and Reproduction, Maastricht, the Netherlands; Department of Dermatology, Maastricht University Medical Centre+, Maastricht University, Maastricht, the Netherlands.
  • Lallas A; First Department of Dermatology, Aristotle University, Thessaloniki, Greece.
  • Leiter U; Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.
  • Malvehy J; Dermatology Department of Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, CIBER de enfermedades raras, Instituto Carlos III, Barcelona Spain.
  • Del Marmol V; Department of Dermatology, University Hospital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
  • Moreno-Ramirez D; Department of Medical and Surgical Dermatology Service, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Pellacani G; Dermatology Unit, University of Rome La Sapienza, Rome, Italy.
  • Peris K; UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endocrino Metaboliche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy; Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Saiag P; Department of General and Oncologic Dermatology, Ambroise-Paré hospital, APHP, and EA 4340 'Biomarkers in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France.
  • Tagliaferri L; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Trakatelli M; Department of Dermatology, Papageorgiou Hospital, Aristotle University Department of Medicine, Thessaloniki, Greece.
  • Ioannides D; First Department of Dermatology, Aristotle University, Thessaloniki, Greece.
  • Vieira R; Department of Dermatology Coimbra Hospital and University Centre, Coimbra, Portugal.
  • Zalaudek I; Department of Dermatology, University of Trieste, Trieste, Italy.
  • Arenberger P; Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Eggermont AMM; University Medical Center Utrecht and Princess Máxima Center, Utrecht, the Netherlands; Comprehensive Cancer Center Munich, Technical University Munich and Ludwig Maximilian University, Munich, Germany.
  • Röcken M; Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.
  • Grob JJ; Aix Marseille University, APHM Hospital, Marseille, France.
  • Lorigan P; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, UK.
Eur J Cancer ; 193: 113251, 2023 Nov.
Article in En | MEDLINE | ID: mdl-37717283
ABSTRACT
Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in white populations, accounting for 20% of all cutaneous malignancies. Overall, cSCC mostly has very good prognosis after treatment, with 5-year cure rates greater than 90%. Despite the overall favourable prognosis and the proportionally rare deaths, cSCC is associated with a high total number of deaths due to its high incidence. A collaboration of multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS), the European Academy of Dermatology and Venereology (EADV) and the European Organization of Research and Treatment of Cancer (EORTC), was formed to update recommendations on cSCC, based on current literature and expert consensus. Part 1 of the guidelines addresses the updates on classification, epidemiology, diagnosis, risk stratification, staging and prevention in immunocompetent as well as immunosuppressed patients.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Guideline Language: En Journal: Eur J Cancer Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Guideline Language: En Journal: Eur J Cancer Year: 2023 Document type: Article